A389030 Stock Overview
GENINUS Inc., a bioinformation analysis company, engages in the research and development, manufacture, and sale of next generation sequencing (NGS) - based genome analysis solutions in South Korea.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
GENINUS Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ₩1,667.00 |
| 52 Week High | ₩6,250.00 |
| 52 Week Low | ₩1,620.00 |
| Beta | 0.62 |
| 1 Month Change | -14.07% |
| 3 Month Change | -21.55% |
| 1 Year Change | -25.58% |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -62.68% |
Recent News & Updates
Shareholder Returns
| A389030 | KR Biotechs | KR Market | |
|---|---|---|---|
| 7D | -4.6% | 0.3% | -0.4% |
| 1Y | -25.6% | 5.7% | 4.5% |
Return vs Industry: A389030 underperformed the KR Biotechs industry which returned 5.7% over the past year.
Return vs Market: A389030 underperformed the KR Market which returned 4.5% over the past year.
Price Volatility
| A389030 volatility | |
|---|---|
| A389030 Average Weekly Movement | 6.3% |
| Biotechs Industry Average Movement | 8.4% |
| Market Average Movement | 5.2% |
| 10% most volatile stocks in KR Market | 11.8% |
| 10% least volatile stocks in KR Market | 2.4% |
Stable Share Price: A389030's share price has been volatile over the past 3 months.
Volatility Over Time: A389030's weekly volatility has decreased from 12% to 6% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2018 | n/a | Woongyang Park | kr-geninus.com |
GENINUS Inc., a bioinformation analysis company, engages in the research and development, manufacture, and sale of next generation sequencing (NGS) - based genome analysis solutions in South Korea. It offers CancerSCAN, an NGS-based cancer genome diagnosis solution; LiquidSCAN, a liquid biopsy NGS test; and Celinus, a single-cell analysis solution for ultra-precise genome analysis. The company also provides HealthSCAN, a genetic test service; WithMe, a service that analyzes gut bacteria characteristics related to the risk of chronic diseases; and OncoSTATION, an automated clinical genome information analysis solution.
GENINUS Inc. Fundamentals Summary
| A389030 fundamental statistics | |
|---|---|
| Market cap | ₩55.48b |
| Earnings (TTM) | -₩9.68b |
| Revenue (TTM) | ₩6.97b |
8.0x
P/S Ratio-5.7x
P/E RatioIs A389030 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| A389030 income statement (TTM) | |
|---|---|
| Revenue | ₩6.97b |
| Cost of Revenue | ₩6.90b |
| Gross Profit | ₩64.63m |
| Other Expenses | ₩9.75b |
| Earnings | -₩9.68b |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -291.00 |
| Gross Margin | 0.93% |
| Net Profit Margin | -139.00% |
| Debt/Equity Ratio | 0% |
How did A389030 perform over the long term?
See historical performance and comparison